Ice Miller partner TaeSoo Sean Kim will be speaking at a presentation titled "The Key to Innovation: Global Open Innovation Strategy" at the 2025 BIO KOREA International Convention.

Click here to view the full agenda.

Program Description:

In the rapidly evolving pharmaceutical and biotechnology industries, open innovation has become a key strategy for driving innovation, accelerating drug development, and maximizing resource efficiency.

Beyond simple research and development (R&D) collaborations, open innovation serves as an essential factor for sustainable growth and industry leadership. To remain competitive in this rapidly changing environment, not only global pharmaceutical companies but also small and mid-sized biotech firms must actively leverage various forms of open innovation, including licensing, joint R&D, partnerships with startups, digital healthcare, and AI-driven technologies.

To effectively utilize open innovation, companies must establish strategic direction, build collaborative models, conduct technology evaluation and licensing strategies, and understand contractual and regulatory considerations. Thorough preparation is essential for fostering successful global partnerships.

This session will explore the latest trends in open innovation within the global pharmaceutical and biotech industries. By examining successful case studies, we will delve into practical strategies for collaboration, licensing, and joint R&D, providing actionable insights for industry professionals.

Session Chair:

• Minji Kim, President, Cross Border Partners, LLC

Speakers:

• Ja Young Kim, Innovation Lead, Novo Nordisk US R&D
• Magnus Björsne, CEO, AstraZeneca BioVentureHub
• Friedemann Janus, SVP, Bayer
• Oliver Kast, Global Head Oncology Business Development and Licensing, Boehringer Ingelheim International GmbH
• Hamish Wright, Senior Vice President, Schrödinger
• Sean Kim, Partner, Ice Miller LLP